Akero Therapeutics Inc (AKRO)

50.90 -2.34 (-4.40%) USD  |  NASDAQ  |  Jun 07, 16:00
50.91 +0.01 (+0.02%) Pre-Market: 20:00
More

Akero Therapeutics News

News

Headline
Wire
Time (ET)
Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View
Yahoo
06/07 12:31
Akero Therapeutics, Inc. (AKRO) Is a Great Choice for 'Trend' Investors, Here's Why
Yahoo
06/07 08:50
HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Keeps Buy Rating
MT Newswires
06/07 08:24
Top Small-Cap Stocks for June 2023
Yahoo
06/06 13:13
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Yahoo
06/06 12:13
Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study
Yahoo
06/06 11:14
Insider Sell: Akero Therapeutics
MT Newswires
06/06 01:46
BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody
Yahoo
06/05 12:43
Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
Yahoo
06/05 11:40
Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study
Yahoo
06/05 10:22
UPDATE 2-Akero says NASH drug shown to reduce liver fat by 65% in some patients
Yahoo
06/05 07:39
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
Yahoo
06/05 07:00
Insider Buying Alert: These 10 Stocks are Seeing Significant Insider Activity
Yahoo
06/02 11:36
Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies
Yahoo
06/02 07:12
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Yahoo
06/01 16:05
J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH
Yahoo
05/31 10:46
Akero Therapeutics to Present at the Jefferies Healthcare Conference
Yahoo
05/31 08:00
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
Yahoo
05/30 10:56
Drug pricing watchdog raises alarm over upcoming liver disease meds
SA Breaking News
05/29 15:00
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
Yahoo
05/29 07:48
Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails
Yahoo
05/26 10:51
INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
Yahoo
05/24 08:14
How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22%
Yahoo
05/23 09:55
Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study
Yahoo
05/17 13:59
Canaccord Genuity Adjusts Price Target on Akero Therapeutics to $59 From $58, Maintains Buy Rating
MT Newswires
05/17 10:15
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
MT Newswires
05/17 09:05
Akero Therapeutics prices $220M offering
SA Breaking News
05/17 05:31
Akero Therapeutics Prices Stock Offering at $42 per Share
MT Newswires
05/17 04:19
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
Globe Newswire
05/16 18:53
HC Wainwright Adjusts Price Target on Akero Therapeutics to $62 From $64, Maintains Buy Rating
MT Newswires
05/16 08:23
We're Interested To See How Akero Therapeutics (NASDAQ:AKRO) Uses Its Cash Hoard To Grow
Yahoo
05/16 06:33
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Yahoo
05/15 07:00
Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep going
Yahoo
05/10 08:50
Why Earnings Season Could Be Great for Akero Therapeutics (AKRO)
Yahoo
05/04 09:21
Insider Sell: Akero Therapeutics
MT Newswires
05/04 06:26
10 Best Small-Cap Growth Stocks to Buy Now
Yahoo
05/04 06:26
Can Akero Therapeutics, Inc. (AKRO) Climb 42.57% to Reach the Level Wall Street Analysts Expect?
Yahoo
04/18 09:55
Akero Therapeutics Discloses 'Positive' FDA Meeting for Liver Failure Treatment -- Shares Rise After Hours
MT Newswires
03/29 17:36
Akero plans to begin Phase 3 trial of NASH treatment in H2 after successful FDA meet
SA Breaking News
03/29 16:38
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
Globe Newswire
03/29 16:01
Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up
Yahoo
03/22 16:09
Top Premarket Decliners
MT Newswires
03/22 08:06
--Canaccord Genuity Adjusts Akero Therapeutics Price Target to $58 From $50, Maintains Buy Rating
MT Newswires
03/20 14:01
Akero Therapeutics Signs Open Market Sale Agreement; May Sell $200 Million Common Shares From Time-to-Time
MT Newswires
03/17 10:46
Akero Therapeutics' Q4 Loss Narrows; Cash Expected to Fund Operations Into 2025
MT Newswires
03/17 07:26
Akero Therapeutics GAAP EPS of -$0.49 beats by $0.31
SA Breaking News
03/17 07:07
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Yahoo
03/17 07:00
Insider Sell: Akero Therapeutics
MT Newswires
03/03 16:26
Insider Sell: Akero Therapeutics
MT Newswires
02/03 17:33
Akero upgraded at Morgan Stanley on NASH prospects
SA Breaking News
01/27 14:18
Morgan Stanley Upgrades Akero Therapeutics to Overweight From Equal Weight, $65 Price Target
MT Newswires
01/27 09:41
Insider Sell: Akero Therapeutics
MT Newswires
01/18 17:35
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
Globe Newswire
01/10 08:00
Insider Sell: Akero Therapeutics
MT Newswires
01/06 07:13
Insider Sell: Akero Therapeutics
MT Newswires
01/05 18:02
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Globe Newswire
01/04 08:00
Insider Sell: Akero Therapeutics
MT Newswires
12/30 16:31
Insider Sell: Akero Therapeutics
MT Newswires
12/29 04:41
MRIN, GOSS and AKRO among pre market losers
SA Breaking News
12/19 08:20
Akero's liver disease drug gets FDA breakthrough therapy tag
SA Breaking News
12/08 08:08
Akero Therapeutics Says FDA Designates its Nonalcoholic Steatohepatitis Treatment Candidate a Breakthrough Therapy
MT Newswires
12/08 07:34
Insider Sell: Akero Therapeutics
MT Newswires
12/02 17:50
IBRX, ALKS and QSI are among after hour movers
SA Breaking News
11/18 17:51
Insider Sell: Akero Therapeutics
MT Newswires
11/14 17:32
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
Globe Newswire
11/10 16:05
--Morgan Stanley Adjusts Price Target on Akero Therapeutics to $40 From $30, Maintains Equalweight Rating
MT Newswires
11/07 11:01
--HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Maintains Buy Rating
MT Newswires
11/07 09:49
Akero Therapeutics Q3 Net Loss Widens
MT Newswires
11/04 09:13
-- Earnings Flash (AKRO) AKERO THERAPEUTICS Posts Q3 Loss $-0.92
MT Newswires
11/04 07:02
Insider Sell: Akero Therapeutics
MT Newswires
11/01 17:41
Insider Sell: Akero Therapeutics
MT Newswires
10/28 07:12
Insider Sell: Akero Therapeutics
MT Newswires
10/17 17:47
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
Globe Newswire
10/11 16:01
Insider Sell: Akero Therapeutics
MT Newswires
10/05 07:16
Akero Therapeutics Closes $230 Million Upsized Common Stock Offering
MT Newswires
09/19 16:08
Insider Sell: Akero Therapeutics
MT Newswires
09/16 07:26
Akero Therapeutics Prices Upsized $200 Million Common Stock Offering
MT Newswires
09/15 03:03
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Globe Newswire
09/14 20:07
Morgan Stanley Raises Price Target on Akero Therapeutics to $30 From $26, Reiterates Equalweight Rating
MT Newswires
09/14 10:04
Evercore ISI Upgrades Akero Therapeutics to Outperform From In-Line, Adjusts Price Target to $50 From $10
MT Newswires
09/14 04:52
Akero Therapeutics Commences $175 Million Public Offering of Common Stock
MT Newswires
09/13 16:08
Sector Update: Health Care Stocks Tumble This Afternoon
MT Newswires
09/13 16:03
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Globe Newswire
09/13 16:01
Update: Akero Therapeutics' Efruxifermin Phase 2b Study Meets Endpoints for NASH Treatment; Shares Soar
MT Newswires
09/13 14:19
Top Midday Gainers
MT Newswires
09/13 13:58
Sector Update: Health Care Stocks Sinking This Afternoon
MT Newswires
09/13 13:41
Wall Street Tumbles Pre-Bell as Traders Digest Higher-Than-Expected August Inflation
MT Newswires
09/13 09:21
Akero Therapeutics Shares Soar Pre-Bell on Efruxifermin Phase 2b Study Meeting Endpoints for NASH Treatment
MT Newswires
09/13 09:06
Thinking about buying stock in Akero Therapeutics, Planet Labs, Kaspien Holdings, Neurobo Pharmaceuticals, or 89Bio?
PR Newswire
09/13 08:30
Top Premarket Gainers
MT Newswires
09/13 08:10
In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
Globe Newswire
09/13 06:00
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
Globe Newswire
09/08 16:01
-- Earnings Flash (AKRO) AKERO THERAPEUTICS Posts Q2 Loss $-0.77
MT Newswires
08/04 16:18
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Globe Newswire
08/04 16:05
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
Globe Newswire
06/27 07:00
ELMS, EMWP and EOSE among mid-day movers
SA Breaking News
06/16 12:54
Thinking about buying stock in Electric Last Mile Solutions, American Airlines, Devon Energy, BP, or Akero Therapeutics?
PR Newswire
06/16 10:55
Akero Therapeutics Secures $25 Million Investment by Pfizer, $100 Million Loan Term Facility from Hercules Capital
MT Newswires
06/16 07:38
Pfizer makes $25M equity investment in Akero
SA Breaking News
06/16 07:21
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
Globe Newswire
06/16 07:00
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH
Globe Newswire
06/13 08:00
-- Earnings Flash (AKRO) AKERO THERAPEUTICS Reports Q1 Loss $-0.74
MT Newswires
05/06 07:05
Akero Therapeutics to Present at Upcoming Healthcare Conferences in May
Globe Newswire
05/02 07:30
Akero Therapeutics Q4 Loss Widens
MT Newswires
02/25 07:53
-- Earnings Flash (AKRO) AKERO THERAPEUTICS Posts Q4 Loss $-0.93
MT Newswires
02/25 07:00
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
02/25 07:00
Akero finishes enrollment in phase 2b trial of efruxifermin in liver disease
SA Breaking News
02/08 13:46
Akero Therapeutics Completes Enrollment of Phase 2b Study of Efruxifermin to Treat Liver Disease
MT Newswires
02/08 10:05
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
Globe Newswire
02/08 08:00
Morgan Stanley Adjusts Akero Therapeutics Price Target to $26 From $29, Maintains Equalweight Rating
MT Newswires
02/01 10:25
--Morgan Stanley Adjusts Akero Therapeutics' Price Target to $29 from $27, Keeps Equalweight Rating
MT Newswires
11/15 10:11
HC Wainwright Adjusts Price Target on Akero Therapeutics to $62 from $64, Keeps Buy Rating
MT Newswires
11/15 10:10
--Canaccord Genuity Adjusts Price Target on Akero Therapeutics to $49 From $46, Keeps Buy Rating
MT Newswires
11/15 09:23
Akero Therapeutics Q3 Loss Widens, Operating Expenses Rise
MT Newswires
11/12 08:43
-- Earnings Flash (AKRO) AKERO THERAPEUTICS Posts Q3 Loss $-0.70
MT Newswires
11/12 07:05
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
Globe Newswire
11/09 16:15
Insider Sell: Akero Therapeutics
MT Newswires
11/05 16:58
Insider Sell: Akero Therapeutics
MT Newswires
11/03 17:56
MIME, LBTYA and PTEN among after hour movers
SA Breaking News
10/19 17:43
Akero Gets FDA Fast-Track Label for Efruxifermin for Liver Inflammation Treatment; Shares Up After Hours
MT Newswires
10/19 16:38
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
Globe Newswire
10/19 16:15
Morgan Stanley Downgrades Akero Therapeutics to Equal-Weight Rating From Overweight, Price Target Adjusted to $27 From $63
MT Newswires
10/19 09:36
Insider Sell: Akero Therapeutics
MT Newswires
10/18 17:05
Insider Sell: Akero Therapeutics
MT Newswires
10/05 16:42
Insider Sell: Akero Therapeutics
MT Newswires
09/17 16:14
Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference
Globe Newswire
09/07 08:00
Insider Sell: Akero Therapeutics
MT Newswires
09/03 16:53
--HC Wainwright Adjusts Akero Therapeutics' Price Target to $64 from $68, Keeps Buy Rating
MT Newswires
08/16 09:54
-- Earnings Flash (AKRO) AKERO THERAPEUTICS Reports Q2 Loss $-0.83
MT Newswires
08/13 07:03
Fate Therapeutics Appoints Yuan Xu to its Board of Directors
Globe Newswire
08/04 08:00
--Chardan Suspends Coverage on Akero Therapeutics at Buy Rating With $82 Price Target
MT Newswires
08/02 11:02
89bio and Viking Therapeutics become BTIG’s top picks in NASH space
SA Breaking News
07/29 14:09
Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment
Globe Newswire
07/08 11:10
Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH
Globe Newswire
06/21 08:00
Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress
Globe Newswire
06/01 08:00
Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Globe Newswire
05/28 16:05
--Chardan Adjusts Akero Therapeutics' Price Target to $82 From $81, Maintains Buy Rating
MT Newswires
05/14 06:26
Akero Therapeutics Q1 Net Loss Widens
MT Newswires
05/13 09:04
-- Earnings Flash (AKRO) AKERO THERAPEUTICS Posts Q1 Loss $-0.43
MT Newswires
05/13 07:01
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Globe Newswire
05/13 07:00
Akero Therapeutics Appoints Yuan Xu to its Board of Directors
Globe Newswire
04/26 08:00
89bio could close the valuation gap with Akero by end of 2021: Cantor
SA Breaking News
04/21 12:38
Akero Randomizes First Patient for Dosing in Phase 2b Study of Efruxifermin in Fatty Liver Disease
MT Newswires
03/23 10:46
Analyst Actions: Morgan Stanley Adjusts Price Target on Akero Therapeutics to $63 From $70, Maintains Overweight Rating
MT Newswires
03/23 08:59
Analyst Actions: HC Wainwright Adjusts Price Target on Akero Therapeutics to $68 From $61, Maintains Buy Rating
MT Newswires
03/23 08:58
Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY)
Globe Newswire
03/23 08:00
Akero Therapeutics Reports 'Positive' Results From Liver Disease Drug Trial; Stock Up 3% After Hours
MT Newswires
03/22 16:22
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
Globe Newswire
03/22 16:01
Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients
Globe Newswire
03/22 06:30
Analyst Actions: Canaccord Genuity Adjusts Akero Therapeutics' Price Target to $46 from $51, Keeps Buy Rating
MT Newswires
03/18 11:01
Analyst Actions: HC Wainwright Adjusts Akero Therapeutics' Price Target to $61 from $64, Keeps Buy Rating
MT Newswires
03/17 09:18
Analyst Actions: Chardan Adjusts Akero Therapeutics' Price Target to $81 From $79, Maintains Buy Rating
MT Newswires
03/17 07:26
Akero Therapeutics Reports Wider Q4 Loss
MT Newswires
03/16 08:49
-- Earnings Flash (AKRO) AKERO THERAPEUTICS Reports Q4 Loss $-0.86
MT Newswires
03/16 08:04
Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
Globe Newswire
03/16 08:00
--Analyst Actions: Guggenheim Initiates Coverage on Akero Therapeutics at Buy Rating, Sets Price Target at $54
MT Newswires
02/26 11:53
Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March
PR Newswire
02/23 16:05
BBBY, RDHL, TTOO and OPCH among after-hours movers
SA Breaking News
01/27 17:47
Akero Therapeutics Reports Additional Positive Data From Phase 2a of Efruxifermin to Treat NASH
MT Newswires
11/13 09:11
Analyst Actions: HC Wainwright Adjusts Akero Therapeutics' Price Target to $64 From $62, Keeps Buy Rating
MT Newswires
11/13 08:56
Akero Therapeutics EPS beats by $0.03
SA Breaking News
11/12 16:41
Akero Therapeutics Reports Third Quarter 2020 Financial Results
PR Newswire
11/12 16:05
Akero Therapeutics To Present At Upcoming Conferences In November
PR Newswire
10/21 16:05
Akero Secures EU Regulator's Priority Medicines Designation For Nonalcoholic Steatohepatitis Drug Candidate
MT Newswires
10/16 08:52
EMA grants PRIME designation to Akero Therapeutics' efruxifermin
SA Breaking News
10/16 07:46
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
PR Newswire
10/16 07:30
Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020
PR Newswire
10/02 07:30
Akero Therapeutics Completes Enrollment of Patients in Expansion Cohort For Study Evaluating Efruxifermin
MT Newswires
09/30 11:29
Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study
PR Newswire
09/30 08:00
Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
PR Newswire
09/28 16:05
Akero to evaluate lead asset in an adaptive Phase 2b/3 NASH trial
SA Breaking News
09/24 08:49
Akero Therapeutics to Follow FDA Guidance on Design of Trial for NASH Treatment
MT Newswires
09/24 08:16
Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance
PR Newswire
09/24 07:30
Analyst Actions: Morgan Stanley Initiates Coverage on Akero Therapeutics With Overweight Rating, $70 Price Target
MT Newswires
09/10 08:02
Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference
PR Newswire
09/09 16:05
Akero Therapeutics Net Loss Narrows, Beats Expectations
MT Newswires
08/12 17:18
Akero Therapeutics EPS beats by $0.05
SA Breaking News
08/12 16:23
Akero Therapeutics Reports Second Quarter 2020 Financial Results
PR Newswire
08/12 16:05
Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate
PR Newswire
07/21 11:00
Analyst Actions: HC Wainwright Lifts Price Target on Akero Therapeutics to $62 From $45, Reiterates Buy Rating
MT Newswires
07/20 10:08
Akero Therapeutics raises $216.4M in equities
SA Breaking News
07/10 16:18
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire
07/10 16:05
Akero Therapeutics prices equity offering at $36
SA Breaking News
07/08 04:35
Akero Therapeutics Prices Common Stock Offering at $36/Share
MT Newswires
07/08 04:12
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
PR Newswire
07/07 20:15
Analyst Actions: Chardan Capital Initiates Coverage on Akero Therapeutics With Buy Rating, $79 Price Target
MT Newswires
07/07 10:05
Akero Therapeutics Proposes Offering of 4.75 Million Shares
MT Newswires
07/06 15:19
Akero Therapeutics readies equity offering
SA Breaking News
07/06 07:12
Akero Therapeutics Announces Proposed Public Offering of Common Stock
PR Newswire
07/06 07:00
After Hours Watch List Scorecard: AKRO, FDX, SCS
MT Newswires
07/01 17:22
Close Update: Stocks End Mixed Amid Vaccine Hopes, Positive US Manufacturing Data; Investors Digest Fed Minutes
MT Newswires
07/01 17:03
Midday Report: Wall Street Climbs Amid Vaccine Hopes, Recovery Signs
MT Newswires
07/01 13:00
TTOO, MMLP, INO and BLNK among midday movers
SA Breaking News
07/01 12:43
Analyst Actions: HC Wainwright Lifts Akero Therapeutics' Price Target to $45 From $33, Reiterates Buy Rating
MT Newswires
07/01 11:05
--Analyst Actions: JPMorgan Lifts Price Target on Akero Therapeutics to $41 From $28, Maintains Overweight
MT Newswires
07/01 11:05
Analyst Actions: Jefferies Raises Akero Therapeutics' Price Target to $48 From $31, Reiterates Buy Rating
MT Newswires
07/01 11:05
Analyst Actions: Canaccord Genuity Lifts Price Target on Akero Therapeutics to $51 From $36, Reiterates Buy Rating
MT Newswires
07/01 11:05
T2 Biosystems among healthcare gainers; Inovio Pharmaceuticals leads the losers
SA Breaking News
07/01 11:00
FDX, BYND among premarket gainers
SA Breaking News
07/01 08:11
Akero reports additional positive data on lead candidate in NASH patients
SA Breaking News
06/30 18:04
MT Newswires After Hours Watch List: AKRO, FDX, SCS
MT Newswires
06/30 17:50
UPS, FDX, GNW and AKCA among after-hours movers
SA Breaking News
06/30 17:37
Akero Therapeutics Reports "Strongly Positive" Trial Data of Efruxifermin in Liver Disease - Stock jumps 35% After-Hours
MT Newswires
06/30 16:54
Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
PR Newswire
06/30 16:05
Akero Therapeutics to announce new data from AKR-001 Phase 2a NASH study
SA Breaking News
06/30 14:07
Akero to release new data on lead candidate in NASH after the close
SA Breaking News
06/30 14:07
Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001
PR Newswire
06/29 16:05
Dosing underway in Akero's expanded cohort of Balanced trial in NASH
SA Breaking News
06/17 09:46
Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial of Non-Alcoholic Steatohepatitis
MT Newswires
06/17 08:21
Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH
PR Newswire
06/17 08:00
Akero Therapeutics Appoints Tom Heyman to its Board of Directors
PR Newswire
06/10 08:00
Akero Therapeutics To Present At The Jefferies Virtual Healthcare Conference
PR Newswire
05/26 16:05
Akero Therapeutics Posts Q1 Net Loss; Company Says Pandemic Has Not Hampered Data Collection for Study
MT Newswires
05/13 16:30
Akero Therapeutics Reports First Quarter 2020 Financial Results
PR Newswire
05/13 16:05
BioCryst Pharmaceuticals among healthcare gainers; Community Health Systems leads the losers
SA Breaking News
04/13 11:01
Akero Therapeutics' AKR-001 Trial in Liver Fat Meets Target at Week-12, Stock Jumps 19%
MT Newswires
03/31 10:50
HAL and APA among premarket gainers
SA Breaking News
03/31 09:17
Akero's lead drug successful in mid-stage NASH study
SA Breaking News
03/31 06:42
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
PR Newswire
03/31 06:00
Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001
PR Newswire
03/30 16:05
Akero Therapeutics Reports Narrower-Than-Expected Q4 Loss
MT Newswires
03/16 15:13
OpGen leads healthcare gainers; Tetraphase Pharmaceuticals tops the losers
SA Breaking News
03/16 11:01
Akero Therapeutics EPS beats by $0.06
SA Breaking News
03/16 07:32
Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
PR Newswire
03/16 07:30
Analyst Actions: HC Wainwright Initiates Akero Therapeutics at Buy With $33 Price Target
MT Newswires
03/02 09:04
Cowen likes Amarin in premarket analyst action
SA Breaking News
03/02 08:47
Cantor upgrades Adverum on positive ADVM-022 data
SA Breaking News
02/10 08:28
Analyst Actions: Canaccord Genuity Initiates Coverage on Akero Therapeutics With Buy Rating, $36 Price Target
MT Newswires
02/10 07:11
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
PR Newswire
01/13 08:00
Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference
PR Newswire
01/08 16:05
FCEL, PLX, CLB and SAVA among midday movers
SA Breaking News
12/31 12:42
Healthcare - Top 5 Gainers / Losers
SA Breaking News
12/31 11:10
Akero Completes Enrollment in Phase 2a Study of AKR-001 for Treatment of NASH
MT Newswires
12/16 16:25
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
PR Newswire
12/16 16:05
Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
PR Newswire
11/13 16:01
Akero Therapeutics Posts Narrower Q3 Loss But Wider Than Expected; Shares Down 8%
MT Newswires
11/12 14:48
Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results
PR Newswire
11/12 07:00
InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform
PR Newswire
11/04 08:00
Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference
PR Newswire
09/04 07:00
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
Globe Newswire
08/20 16:05
Akero Therapeutics Q2 EPS Misses Estimate
MT Newswires
08/12 08:29
Akero Therapeutics EPS misses by $1.76
SA Breaking News
08/12 07:08
Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
PR Newswire
08/12 07:00
Analyst Actions: JPMorgan Starts Akero Therapeutics at Overweight, With $28 Price Target
MT Newswires
07/15 09:53
Analyst Actions: Roth Capital Starts Akero Therapeutics at Buy, With $34 Price Target
MT Newswires
07/15 09:52
Analyst Actions: Jefferies Starts Akero Therapeutics at Buy
MT Newswires
07/15 09:13
Wells sees 33% upside in Gilead in premarket analyst action
SA Breaking News
07/15 07:38
Akero Therapeutics Doses First Patient in Study to Treat Fatty Liver Disease
MT Newswires
07/02 16:31
Mid-stage study underway for Akero's NASH candidate AKR-001
SA Breaking News
07/02 16:16
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
PR Newswire
07/02 16:05